Quote Overview

Stock Activity

Open	92.76
Day Low	90.47
Day High	94.98
52 Wk Low	43.89
52 Wk High	101.00
Avg. Volume	583,126
Market Cap	5.55 B
Dividend	NA
Beta	0.63

Key Earnings Data

Earnings ESP	16.92%
Most Accurate Est	-1.36
Current Qtr Est	-1.64
Current Yr Est	-5.41
Exp Earnings Date	^*BMO5/2/24
Prior Year EPS	-8.37
Exp EPS Growth (3-5yr) 34.00%
Forward PE	NA
PEG Ratio	NA

Medical » Medical - Biomedical and Genetics

*BMO = Before Market Open *AMC = After Market Close

Research Reports for BPMC

All Zacks’ Analyst Reports

Premium Research for BPMC

Style Scores F Value D Growth C Momentum F VGM
Zacks Rank	Buy 2
Zacks Industry Rank	Top 30%(75 out of 252)
Zacks Sector Rank	Top 25% (4 out of 16)
Earnings ESP	16.92%
Research Reports for BPMC Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Blueprint Medicines	BPMC
ADMA Biologics	ADMA
ANI Pharmaceuticals	ANIP
Basilea Pharmaceutica	BPMUF
Cidara Therapeutics	CDTX
Cytek Biosciences	CTKB
Entera Bio	ENTX

See all Medical - Biomedical and Genetics Peers

Zacks News for BPMC

No Record found.

Company Summary

Cambridge, MA-based Blueprint Medicines Corporation is a biopharmaceutical company, focused on developing potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

Blueprint Medicines lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, was approved by the Food and Drug Administration (FDA) to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) in January 2020. The drug was approved in Europe in September 2020. In 2023, Ayvakit generated sales worth $204.2 million, up 84% year over year. In June 2021, the FDA approved Ayvakit for treating advanced SM. In May 2023, the FDA expanded Ayvakit’s label to include the treatment of indolent SM in adults. The drug is also approved in Europe for advanced and indolent SM.

Gavreto (pralsetinib) is approved for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The drug is also approved for RET-mutant and RET fusion-positive thyroid cancer. Blueprint Medicines was co-developing Gavreto with Roche. However, following Roche’s decision to discontinue the collaboration agreement, Blueprint is set to regain the global commercial rights to Gavreto in late February.

Fisogatinib is being evaluated in the phase I program for administering it to patients with hepatocellular carcinoma (HCC). Meanwhile, eenestinib (BLU-263) is currently being developed for treating indolent SM (in a phase II/III HARBOR study) and other mast cell disorders. Blueprint Medicines has a collaboration agreement with CStone Pharmaceuticals for the development and commercialization of three clinical-stage candidates in Mainland China, Hong Kong, Macau, and Taiwan.

Blueprint Medicines currently draws revenues from Ayvakit sales and collaboration revenues primarily generated from the agreements with CStone and Roche.

Blueprint also nominated BLU-808, an oral KIT inhibitor as a development candidate for the treatment of mast cell disorders, including chronic urticaria.

For 2023, Blueprint Medicines generated total revenues of $249.4 million compared with $204 million recorded in 2022.